(Q38505125)

3 September 2017

title

New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. (English)

1 reference

3 September 2017

Chae YS

1

1 reference

3 September 2017

Sohn SK

2

1 reference

3 September 2017

Kim JG

3

1 reference

3 September 2017

Cho YY

4

1 reference

3 September 2017

Moon JH

5

1 reference

3 September 2017

Shin HJ

6

1 reference

3 September 2017

Chung JS

7

1 reference

3 September 2017

Cho GJ

8

1 reference

3 September 2017

Yang DH

9

1 reference

3 September 2017

Lee JJ

10

1 reference

3 September 2017

Kim YK

11

1 reference

3 September 2017

Kim HJ

12

1 reference

3 September 2017

language of work or name

English

0 references

publication date

16 July 2007

1 reference

Bone Marrow Transplantation

3 September 2017

published in

1 reference

3 September 2017

volume

40

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

541-547

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705770

3 September 2017

exact match

0 references

cites work

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Cellular and clinical pharmacology of fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705770

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705770

1 reference

Dimensions Publication ID

3 September 2017

1049898813

0 references

1 reference